Literature DB >> 16534101

The natural history of primary lateral sclerosis.

P H Gordon1, B Cheng, I B Katz, M Pinto, A P Hays, H Mitsumoto, L P Rowland.   

Abstract

OBJECTIVE: To define the syndrome of primary lateral sclerosis (PLS) and disorders that contain features of both ALS and PLS, to determine the time beyond which PLS is less likely to become ALS clinically, and to determine the outcome of people with PLS and those who develop lower motor neuron (LMN) signs.
METHODS: The authors reviewed the records of all 39 patients initially diagnosed with PLS in 1984 to 2004. Diagnostic subgroups were defined based on clinical features. The authors used Kaplan-Meier methods to estimate the time to diagnosis, linear regression analyses to assess function, and a Cox proportional hazard model to assess survival in subgroups.
RESULTS: Of the 39 patients, 29 had only upper motor neuron (UMN) signs on initial evaluation. Thirteen of the 29 were later classified as having UMN-dominant ALS (UMN-D) because they acquired evidence of denervation by EMG (3.17 years) or examination (3.67 years). Sixteen of the 29 patients, classified as clinically pure PLS, retained only UMN signs and a normal EMG (mean follow-up 8.7 years). Ten patients who met criteria for ALS at the initial visit were used as controls. The UMN-dominant ALS group had lower functional scores (p = 0.033) than the PLS group, and similar scores to those with ALS. Survival was longer in both the PLS group (p = 0.027) and the UMN-D group (p = 0.067) than the ALS group.
CONCLUSIONS: Clinically pure PLS can be defined by isolated UMN signs 4 years after symptom onset, and is a syndrome of slow progression with high levels of function. Prior to the fourth year, the diagnosis of PLS cannot be made with certainty because many patients develop LMN signs. UMN-dominant ALS, defined by predominantly UMN disease with minor LMN signs, has disability similar to ALS, but slower progression.

Entities:  

Mesh:

Year:  2006        PMID: 16534101     DOI: 10.1212/01.wnl.0000200962.94777.71

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  83 in total

1.  Advances in the application of MRI to amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Michel Modo
Journal:  Expert Opin Med Diagn       Date:  2010-11

2.  High T2 signal in primary lateral sclerosis supports the topographic distribution of fibers in the corpus callosum: assessing disease in the primary motor segment.

Authors:  S M Riad; H Hathout; J C Huang
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

Review 3.  The epidemiology of ALS: a conspiracy of genes, environment and time.

Authors:  Ammar Al-Chalabi; Orla Hardiman
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

4.  Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population.

Authors:  Christina N Fournier; Alyssa Murphy; Lorena Loci; Hiroshi Mitsumoto; Catherine Lomen-Hoerth; Yasushi Kisanuki; Zachary Simmons; Nicholas J Maragakis; April L McVey; Tawfiq Al-Lahham; Terry D Heiman-Patterson; Jinsy Andrews; Erin McDonnell; Merit Cudkowicz; Nazem Atassi
Journal:  J Clin Neuromuscul Dis       Date:  2016-03

5.  Amyotrophic lateral sclerosis presenting as upper limb weakness in a 35 year old female: a case report.

Authors:  Leif A Sigurdson
Journal:  J Can Chiropr Assoc       Date:  2011-09

6.  Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS.

Authors:  Charlotte J Stagg; Steven Knight; Kevin Talbot; Mark Jenkinson; Andrew A Maudsley; Martin R Turner
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

7.  Pattern of spread and prognosis in lower limb-onset ALS.

Authors:  Martin R Turner; Alice Brockington; Jakub Scaber; Hannah Hollinger; Rachael Marsden; Pamela J Shaw; Kevin Talbot
Journal:  Amyotroph Lateral Scler       Date:  2010-08

8.  Survival profiles of patients with frontotemporal dementia and motor neuron disease.

Authors:  William T Hu; Harro Seelaar; Keith A Josephs; David S Knopman; Bradley F Boeve; Eric J Sorenson; Leo McCluskey; Lauren Elman; Helenius J Schelhaas; Joseph E Parisi; Benno Kuesters; Virginia M-Y Lee; John Q Trojanowski; Ronald C Petersen; John C van Swieten; Murray Grossman
Journal:  Arch Neurol       Date:  2009-11

9.  Progressive supranuclear palsy and primary lateral sclerosis secondary to globular glial tauopathy: a case report and a practical theoretical framework for the clinical prediction of this rare pathological entity.

Authors:  Andy J Liu; Jessica E Chang; Georges Naasan; Adam L Boxer; Bruce L Miller; Salvatore Spina
Journal:  Neurocase       Date:  2020-02-23       Impact factor: 0.881

10.  Disease spread through contiguity and axonal tracts in primary lateral sclerosis.

Authors:  Lauren Flynn; Matthew Stephen; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2014-01-27       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.